Short report: Assessment of CD8+ T cell differentiation in Trypanosoma cruzi-infected children

American Journal of Tropical Medicine and Hygiene

Volumn 82, Issue 5, 2010, Pages 861-864

  Albareda, María Cecilia ^a   Olivera, Gabriela Carina ^a   De Rissio, Ana María ^a   Postan, Miriam ^a  

^a Instituto Nacional de Parasitologia   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD57 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 7 RECEPTOR; CYTOKINE; LEUKOCYTE ANTIGEN;

ADOLESCENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CHAGAS DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GROUPS BY AGE; HUMAN; IMMUNE SYSTEM; PROTEIN EXPRESSION; SCHOOL CHILD; ANIMAL; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

ADOLESCENT; ANIMALS; ANTIGENS, CD; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHAGAS DISEASE; CHILD; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; TRYPANOSOMA CRUZI;

EID: 77952708953     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0604     Document Type: Article

References (25)

1. Dias E, Laranja FS, Miranda A, Nobrega G, 1956. Chagas' disease: a clinical, epidemiologic, and pathologic study. Circulation 14: 1035-1060.
2. World Health Organization, 2002. Control of Chagas disease: report of a WHO expert committee. World Health Organ Tech Rep Ser 905: 1-109.
3. Tarleton RL, 2007. Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 19: 430-434.
4. Parish IA, Kaech SM, 2009. Diversity in CD8+ T cell differentiation. Curr Opin Immunol 21: 291-297.
5. + T cell selection, function, and death in the primary immune response in vivo. J Clin Invest 106: 1251-1261.
6. Harari A, Rizzardi GP, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Kaufmann D, Telenti A, Sahli R, Tambussi G, Kaiser L, Lazzarin A, Perrin L, Pantaleo G, 2002. Analysis of HIV-1 and CMV-specific memory CD4 T cell responses during primary and chronic infection. Blood 100: 1381-1387. (Pubitemid 34864295)
7. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF, 2003. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 198: 903-911. (Pubitemid 37152927)
8. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A, Easterbrook P, Dunbar PR, Shepherd D, Cerundolo V, Emery V, Griffiths P, Conlon C, McMichael AJ, Richman DD, Rowland-Jones SL, Appay V, 2004. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2: E20.
9. Nikolich-Zugich J, 2008. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol 8: 512-522. (Pubitemid 351913675)
10. Laucella SA, Postan M, Martin D, Hubby-Fralish B, Albareda MC, Alvarez MG, Lococo B, Barbieri G, Viotti R, Tarleton RL, 2004. The frequency of IFN-γ-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 189: 909-918. (Pubitemid 38328193)
11. + T cells in chronic Chagas disease patients. Int Immunol 18: 465-471. (Pubitemid 43329609)
12. + T cells specific for Trypanosoma cruzi in chronic Chagas disease. PLoS Negl Trop Dis 2: e288.
13. + T cells to immune senescence. J Immunol 183: 4103-4108.
14. Seki Y, Yang J, Okamoto M, Tanaka S, Goitsuka R, Farrar MA, Kubo M, 2007. IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. J Immunol 178: 262-270. (Pubitemid 46033609)
15. Rabin RL, Roederer M, Maldonado Y, Petru A, Herzenberg LA, Herzenberg LA, 1995. Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. J Clin Invest 95: 2054-2060.
16. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho OA, 2006. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol 64: 554-563. (Pubitemid 44536341)
17. Bahia-Oliveira LM, Gomes JA, Cancado JR, Ferrari TC, Lemos EM, Luz ZM, Moreira MC, Gazzinelli G, Correa-Oliveira R, 2000. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J Infect Dis 182: 634-638. (Pubitemid 30651066)
18. Bahia-Oliveira LM, Gomes JA, Rocha MO, Moreira MC, Lemos EM, Luz ZM, Pereira ME, Coffman RL, Dias JC, Cançado JR, Gazzinelli G, Corrêa-Oliveira R, 1998. IFN-gamma in human Chagas' disease: protection or pathology? Braz J Med Biol Res 31: 127-131.
19. Laucella SA, Perez Mazliah D, Bertocchi G, Alvarez AM, Cooley G, Viotti R, Albareda MC, Lococo B, Postan M, Tarleton RL, 2009. Changes in Trypanosoma cruzi-specific immune responses following treatment: surrogate markers of treatment efficacy. CID 49: 1675-1684.
20. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C, 1998. Efficacy of treatment with benznidazole in children. Am J Trop Med Hyg 59: 526-529.
21. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM, 1996. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 9039: 1407-1413. (Pubitemid 26395235)
22. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A, 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734. (Pubitemid 46780632)
23. Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A, 2009. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 95: 524-534.
24. Laucella S, Segura E, Riarte A, Sosa Estani S, 1999. Soluble platelet (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease. Clin Exp Immunol 118: 423-427.
25. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, de Lana M, Pinto Dias JC, Teixeira-Carvalho A, Elói-Santos SM, Martins-Filho OA, 2008. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect 10: 103-113.